Active substanceMometasone + [Heparin sodium]Mometasone + [Heparin sodium] Similar drugsTo uncover Skinlight® cream externally NIZHFARM, JSC Russia Dosage form: & nbspCream for external use. Composition:1 g of cream contains:active ingredients: mometasone furoate 0.1 mg, heparin sodium 60 IU (0.5 mg with heparin sodium activity 120 IU / mg);Excipients: paraffin liquid 100 mg, vaseline 100 mg, propylene glycol 150 mg, stearic acid 50-10 mg, distilled monoglycerides 10 mg, glycerol 50 mg, macrogol cetostearate 10 mg, poloxamer (emixol 268) 5 mg, cetostearyl alcohol (cetyl alcohol is not more than 60%, stearyl alcohol is not less than 40%) - 25 mg, imidourea - 2 mg, butylhydroxytoluene - 1 mg, water - up to 1 g. Description:Cream white or white with a yellowish tint of color, odorless. Pharmacotherapeutic group:Glucocorticosteroid is a combination for topical application. ATX: & nbspD.07.X.C.03 Mometasone in combination with other drugs Pharmacodynamics:Mometasone furoate - Glucocorticosteroid for topical application. Has anti-inflammatory, anti-allergic, antipruritic and anti-exudative action. It inhibits the release of inflammatory mediators. Increases the production of lipocortin, which is an inhibitor of phospholipase A2, which causes inhibition of the release of arachidonic acid.It prevents the accumulation of neutrophils, which reduces inflammatory exudate and production of cytokines, inhibits the migration of macrophages, leads to a decrease in the processes of infiltration and granulation.Reduces inflammation due to a decrease in the formation of the chemotaxis substance (effect on the "late" allergy reaction), inhibits the development of an "immediate" allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).Heparin is an anticoagulant of direct action, it has anti-inflammatory, antiproliferative, anti-edematous and analgesic effect. Reduces platelet aggregation, binds to antithrombin III, preventing the passage of prothrombin in thrombin. Oppresses the activity of thrombin. Reduces the activity of hyaluronidase, increases the fibrinolytic properties of the blood. Heparin improves microcirculation and activates tissue metabolism, thereby accelerating the processes of resorption of hematomas and thrombi, eventually restoring the permeability of veins, clinically it is accompanied by a pronounced analgesic and anti-inflammatory effect. Pharmacokinetics:Absorption of the cream is negligible. 8 hours after application to the intact skin (without occlusive dressing), 0.4% mometasone is found in the systemic circulation. An insignificant amount of heparin is absorbed from the surface of the skin into the systemic circulation. The maximum concentration of heparin in the blood is noted 8 hours after the application. The elimination of heparin, mainly occurs through the kidneys, half-life of 12 hours. Indications:Diseases of the skin (including chronic course), amenable to glucocorticosteroid therapy for external use: psoriasis, atopic dermatitis, simple chronic lichen (limited neurodermatitis), eczema, itchy dermatoses, insect bites, 1st degree burns, sunburn, red flat lichen , discoid lupus erythematosus. Contraindications:- hypersensitivity to the components of the drug or glucocorticosteroids;- rosacea, perioral dermatitis;- bacterial, viral (Herpes simplex, Herpes zoster, chicken pox), fungal skin infection;- tuberculosis, syphilis;- postvaccinal reactions;- Pregnancy (treatment of extensive skin areas, long-term treatment);- the period of breastfeeding;- Children under 18 years. Carefully:Applying to the face skin and intertriginoznuyu surface of the skin, the use of occlusive dressings, use in large areas of the skin and / or for a long time. Long-term therapy with glucocorticosteroids of systemic action. Pregnancy and lactation:The safety of the cream for external application of Skinlight® during pregnancy and lactation has not been studied. Glucocorticosteroids penetrate the placental barrier. Prescribe when pregnant if the intended benefit to the mother exceeds the potential risk to the fetus; while using small doses and applying a short time.Glucocorticosteroids are excreted in breast milk. If it is necessary to use the drug during lactation, breastfeeding should be stopped. Dosing and Administration:Outwardly. The cream is applied to the affected skin with a thin layer once a day. The duration of treatment is 7-28 days and depends on the nature and severity of the disease. With limited vulgar psoriasis, the duration of treatment is 21 days. Side effects:Local reactions: burning, itching, paresthesia, folliculitis, acne, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, attachment of secondary infection, striae, sweating.When external forms of glucocorticosteroids are used for a long time and / or for the treatment of large areas of the skin (the total area of application is larger than the palm of the patient), or with the use of occlusive dressings, there may be side effects typical of systemic glucocorticosteroids, including adrenal insufficiency and Cushing's syndrome. Overdose:Symptoms: oppression of the hypothalamic-pituitary-adrenal system, including secondary adrenal insufficiency.Treatment: symptomatic, if necessary - correction of electrolyte imbalance, drug withdrawal (with prolonged therapy - gradual abolition). Interaction:Data on the interaction of the drug with other drugs are absent. Special instructions:When applied on large areas of the skin for a long time, especially when using occlusive dressings,it is possible that glucocorticosteroids enter the systemic circulation and develop the systemic action of glucocorticosteroids. Given this, patients should be observed in terms of signs of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome.During the period of treatment, it is recommended to regularly monitor the function of the adrenal glands. If side effects occur, treatment should be discontinued and symptomatic therapy should be prescribed. When joining a secondary infection, antimicrobial therapy.Avoid contact with the eyes.Propylene glycol, which is part of the preparation, may cause irritation at the site of application. In such cases, discontinue use of the drug and prescribe appropriate treatment.It should be borne in mind that glucocorticosteroids are capable of altering the manifestations of certain skin diseases, which can make diagnosis more difficult. In addition, the use of glucocorticosteroids may be the cause of delayed wound healing.With prolonged therapy with glucocorticosteroids, sudden discontinuation of therapy can lead to the development of a rebound syndrome, manifested in the form of dermatitis with intense reddening of the skin and a burning sensation.Therefore, after a long course of treatment, the drug should be canceled gradually, for example, by switching to an intermittent treatment regimen before it is completely discontinued. Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive and other mechanisms. Form release / dosage:Cream for external use 100 μg + 60 IU / g. Packaging:For 15 g in aluminum tubes or in tubes polyethylene laminated. Each tube together with instructions for medical use of the drug is placed in a pack of cardboard. Storage conditions:At a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:2 years. Do not use the drug after the expiration date. Terms of leave from pharmacies:On prescription Registration number:PL-000924 Date of registration:18.10.2011 / 20.04.2016 Expiration Date:18.10.2016 The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia Manufacturer: & nbspNIZHFARM, JSC Russia Information update date: & nbsp2016-10-19 Illustrated instructions × Illustrated instructions Instructions